search

Active clinical trials for "Arthritis"

Results 931-940 of 3640

Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid...

Rheumatoid Arthritis (RA)

This is a Phase III study to evaluate efficacy and safety of Tocilizumab in patients with Rheumatoid Arthritis.

Completed9 enrollment criteria

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior...

Rheumatoid Arthritis

This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on study treatment is 48 weeks.

Completed8 enrollment criteria

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Rheumatoid Arthritis

The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.

Completed12 enrollment criteria

Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid...

Rheumatoid Arthritis

The purpose of this study is to compare the efficacy and safety of intra-articular glucocorticoid injection to its systemic use for treatment of knee synovitis in patients with Rheumatoid Arthritis

Completed15 enrollment criteria

Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid...

Active Rheumatoid Arthritis

To compare the therapeutic and radiographic effects and safety between etanercept, methotrexate, and the etanercept/methotrexate combination in patients with rheumatoid arthritis.

Completed4 enrollment criteria

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Rheumatoid Arthritis

The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.

Completed5 enrollment criteria

A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

Rheumatoid Arthritis

The purpose of this study was to demonstrate similarity of NI-071 (proposed biosimilar to infliximab) to US REMICADE® (reference product) in terms of safety and efficacy in participants with rheumatoid arthritis (RA) not adequately responding to methotrexate (MTX).

Completed19 enrollment criteria

Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis

Psoriatic Arthritis

The purpose of this study is: To elucidate the immunomodulating properties of anti-TNF-α therapy in patients with psoriatic arthritis (PsA). To ascertain whether magnetic resonance imaging (MRI) is a sensitive tool in measuring early response after therapy with anti-TNF-α in the PsA wrist using the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) guidelines for rheumatoid arthritis (RA). To assess whether the lipid and other cardiovascular risk profiles would improve after anti-TNF-α therapy in patients with PsA.

Completed22 enrollment criteria

Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis

ArthritisRheumatoid

CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate

Completed5 enrollment criteria

Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis...

ArthritisRheumatoid

The objective of this study is to compare in Chinese subjects with rheumatoid arthritis (RA) the efficacy and safety in this subject population of 50 mg once-weekly injections of etanercept versus placebo in subjects receiving methotrexate. This is a multi-center, double-blind, randomized, parallel and placebo-controlled outpatient study. Approximately 150 subjects will participate in this study for about 18 weeks including a screening period up to 4 weeks, 12-week treatment period, and a 2-week follow-up period at approximately 25 sites.

Completed4 enrollment criteria
1...939495...364

Need Help? Contact our team!


We'll reach out to this number within 24 hrs